To discuss the application of iPSC-derived SC-islet models in studying monogenic beta cell disorders, particularly MODY and congenital hyperinsulinism.
Key Findings:
iPSC-derived SC-islets can model key aspects of monogenic beta cell disorders, including defects in insulin secretion and developmental trajectories.
Studies have shown that transcription factor dysfunction can disrupt insulin secretion and beta cell maturation in MODY subtypes.
Congenital hyperinsulinism has been modeled using iPSC-derived SC-islets to study excess insulin secretion and increased beta cell proliferation.
Interpretation:
iPSC technology provides a powerful platform for understanding the mechanisms underlying monogenic beta cell disorders and for developing targeted therapies.
Limitations:
Incomplete functional maturation of SC-islets.
Variability across different differentiation protocols.
Conclusion:
iPSC-derived SC-islets represent a transformative approach for mechanistic discovery and personalized treatment in monogenic beta cell disorders.
